La chaîne d'options affiche les données clés des options sur actions de Spyre Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Spyre Therapeutics..

Spyre Therapeutics (NASDAQ:SYRE) Stock, Chaîne d'Options

Spyre Therapeutics

Aeglea BioTherapeutics

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Spyre Therapeutics Inc

WIIM

RDHL

RedHill shares are trading higher after the company announced an exclusive licensing agreement with Hyloris Pharmaceuticals for RHB-102, including an upfront payment and up to $60 million in potential milestones.

<ul>
<li>Food Processing to be a Fast-Growing and Nimble Standalone Business with Best-in-Class Technologies for Industrial Protein, Bakery, and Snack Processors</li>
<li>Middleby RemainCo Well-Positioned to Drive Sustainable Growth and Margin Expansion Through Innovation Leadership and Differentiated Go-To-Market Capabilities in Commercial Foodservice and Residential Kitchens</li>
<li>Separation of Food Processing Expected to be Achieved Through Tax-Free Spin-Off and be Completed Early 2026</li>
<li>Company Separately Announces Q4 and Full-Year 2024 Financial Results and Appointment of Independent Directors to its Board</li>
</ul>

News

MIDD

Middleby To Spin Off Food Processing Unit, Forming Independent Food Processing And Kitchen Equipment Leaders

RedHill Enters Exclusive Development And Commercialization Licensing Agreement With Hyloris Pharmaceuticals For RHB-102; Hyloris Will Pay Co. Upfront Payment And Up To $60M In Potential Milestones

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. The Company expects Adjusted Gross Profit Margin to be in the range of 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $225 million to $235 million and Adjusted Diluted EPS to be in the range of $3.35 to $3.55. The Company's guidance assumes no significant changes in foreign exchange rates.
For the first quarter of 2025, the Company expects GAAP revenue of approximately $232 million to $236 million. The Company expects Adjusted Gross Profit Margin to be in the range of 46.0% to 46.5%. The Company expects Adjusted EBITDA to be in the range of $48 million to $51 million and Adjusted Diluted EPS to be in the range of $0.63 to $0.71. The Company's guidance assumes no significant changes in foreign exchange rates.

Guidance

NOVT

Novanta Expects Q1 Revenue Of $232M-$236M Vs $244.89M Est, Adj EPS Of $0.63-$0.71 Vs $0.78 Est

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.27 by 25.93 percent. The company reported quarterly sales of $856.65 million which beat the analyst consensus estimate of $829.19 million by 3.31 percent. This is a 0.18 percent decrease over sales of $858.23 million the same period last year.

Earnings

Earnings Beats

AHCO

AdaptHealth Q4 2024 GAAP EPS $0.34 Beats $0.27 Estimate, Sales $856.65M Beat $829.19M Estimate

Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) reported quarterly losses of $(2.54) per share which beat the analyst consensus estimate of $(2.81) by 9.61 percent. This is a 73.97 percent decrease over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $2.37 billion which missed the analyst consensus estimate of $2.58 billion by 7.84 percent. This is a 41.38 percent decrease over sales of $4.05 billion the same period last year.

Earnings Misses

Delek US Hldgs Q4 2024 Adj EPS $(2.54) Beats $(2.81) Estimate, Sales $2.37B Miss $2.58B Estimate

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

OFIX

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 103.39 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $215.66 million which beat the analyst consensus estimate of $212.71 million by 1.38 percent. This is a 7.61 percent increase over sales of $200.41 million the same period last year.

Orthofix Medical Q4 Adj $0.02 Beats $(0.05) Estimate, Sales $215.66M Beat $212.71M Estimate

Sealed Air Sees FY25 Revenue Of $5.100B - $5.500B Vs. $5.4B Est; Adj EPS Of $2.90 - $3.30 Vs. $3.12 Est.

2025 Financial Guidance: We expect revenue growth to be in the range of 15% to 17%. In addition, we anticipate gross margin to be in the range of 73% - 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%. Additionally, we expect to be net cash flow positive for the full year.

Biotech

Health Care

General

AXGN

Axogen Expects 2025 Revenue Growth Of 15%-17%, The Company Expects Gross Margin Of 73%-75%

Guidance for Fiscal Year 2025
The Company is providing its financial guidance for fiscal year 2025, as follows:
<ul>
<li>Net revenue of $3.22 billion to $3.36 billion;</li>
<li>Adjusted EBITDA of $670 million to $710 million;</li>
<li>Free cash flow of $180 million to $220 million</li>
</ul>

AdaptHealth Sees FY2025 Sales $3.220B-$3.360B vs $3.33B Est

CECO

CECO Continues To See FY25 Revenue $700M-$750M And Adj. EBITDA $90M-$100M

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly sales of $856.65 million which beat the analyst consensus estimate of $829.19 million by 3.31 percent. This is a 0.18 percent decrease over sales of $858.23 million the same period last year.

AdaptHealth Q4 Sales $856.65M Beat $829.19M Estimate

SHLS

Shoals Technologies Gr Q4 2024 Adj. EPS $0.08 Misses $0.10 Estimate, Sales $106.987M Beat $102.106M Estimate

Delek Logistics Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.62 by 9.68 percent. The company reported quarterly sales of $209.86 million which missed the analyst consensus estimate of $240.05 million by 12.57 percent. This is a 17.43 percent decrease over sales of $254.15 million the same period last year.

Delek Logistics Partners Q4 2024 GAAP EPS $0.68 Beats $0.62 Estimate, Sales $209.86M Miss $240.05M Estimate

Stephens &amp; Co. analyst Jim Salera maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and raises the price target from $420 to $440.

Price Target

Analyst Ratings

Stephens & Co. Maintains Equal-Weight on Domino's Pizza, Raises Price Target to $440

Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.03 by 133.33 percent. This is a 216.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $49.41 million which beat the analyst consensus estimate of $48.57 million by 1.72 percent. This is a 15.16 percent increase over sales of $42.90 million the same period last year.

Axogen Q4 2024 Adj EPS $0.07 Beats $0.03 Estimate, Sales $49.41M Beat $48.57M Estimate

Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.67 by 11.94 percent. This is a 14.77 percent decrease over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $1.37 billion which beat the analyst consensus estimate of $1.36 billion by 0.96 percent. This is a 0.36 percent decrease over sales of $1.38 billion the same period last year.

Sealed Air Q4 Adj $0.75 Beats $0.67 Estimate, Sales $1.37B Beat $1.36B Estimate

CECO Environmental Q4 2024 Adj. EPS $0.27 Beats $0.26 Estimate, Sales $158.566M Miss $159.755M Estimate

Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) reported quarterly earnings of $2.88 per share which beat the analyst consensus estimate of $2.55 by 12.94 percent. This is a 8.68 percent increase over earnings of $2.65 per share from the same period last year. The company reported quarterly sales of $1.01 billion which beat the analyst consensus estimate of $998.00 million by 1.60 percent. This is a 0.50 percent increase over sales of $1.01 billion the same period last year.

Comments

Spyre Therapeutics

Spyre Therapeutics (SYRE) Options

Spyre Therapeutics (NASDAQ:SYRE) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL